IDEXX Laboratories (NASDAQ:IDXX) Shares Cross Above 200-Day Moving Average – Time to Sell?

Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) crossed above its 200-day moving average during trading on Thursday. The stock has a 200-day moving average of $574.96 and traded as high as $576.17. IDEXX Laboratories shares last traded at $575.98, with a volume of 477,765 shares changing hands.

Wall Street Analyst Weigh In

IDXX has been the topic of several recent research reports. The Goldman Sachs Group started coverage on shares of IDEXX Laboratories in a research report on Friday, October 16th. They issued a “buy” rating and a $740.00 price target on the stock. Jefferies Financial Group cut their price objective on shares of IDEXX Laboratories from $795.00 to $705.00 and set a “buy” rating for the company in a research report on Tuesday, October 20th. UBS Group reduced their price objective on IDEXX Laboratories from $670.00 to $627.00 and set a “neutral” rating for the company in a research note on Tuesday. Leerink Partners decreased their target price on IDEXX Laboratories from $725.00 to $715.00 and set an “outperform” rating on the stock in a report on Monday, July 13th. Finally, Barclays lowered their target price on IDEXX Laboratories from $800.00 to $710.00 and set an “overweight” rating on the stock in a research report on Tuesday, August 11th. Nine analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $727.69.

IDEXX Laboratories Stock Performance

The stock has a market cap of $45.38 billion, a P/E ratio of 40.50 and a beta of 1.55. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.17 and a quick ratio of 0.87. The firm’s 50-day moving average price is $534.16 and its 200-day moving average price is $574.96.

IDEXX Laboratories (NASDAQ:IDXX) last issued its earnings results on Tuesday, August 4th. The company reported $4.27 earnings per share for the quarter, topping analysts’ consensus estimates of $3.94 by $0.33. The firm had revenue of $1.22 billion during the quarter, compared to analyst estimates of $1.20 billion. IDEXX Laboratories had a net margin of 25.03% and a return on equity of 71.96%. IDEXX Laboratories’s revenue for the quarter was up 9.7% on a year-over-year basis. During the same quarter in the prior year, the business earned $3.50 earnings per share. IDEXX Laboratories has set its FY 2026 guidance at 14.690-14.940 EPS. Sell-side analysts expect that IDEXX Laboratories, Inc. will post 14.81 earnings per share for the current fiscal year.

Insider Activity at IDEXX Laboratories

In other IDEXX Laboratories news, Director Lawrence D. Kingsley sold 2,203 shares of the stock in a transaction dated Friday, September 4th. The shares were sold at an average price of $532.08, for a total transaction of $1,172,172.24. Following the completion of the transaction, the director owned 9,568 shares of the company’s stock, valued at $5,090,941.44. This represents a 18.72% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 0.79% of the stock is owned by company insiders.

Institutional Investors Weigh In On IDEXX Laboratories

A number of hedge funds have recently made changes to their positions in IDXX. Bank of New York Mellon Corp purchased a new position in IDEXX Laboratories during the 2nd quarter valued at approximately $628,223,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in shares of IDEXX Laboratories by 4.6% during the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 911,489 shares of the company’s stock worth $479,844,000 after acquiring an additional 39,700 shares in the last quarter. Arrowstreet Capital Limited Partnership raised its holdings in shares of IDEXX Laboratories by 52.4% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 838,839 shares of the company’s stock worth $471,335,000 after acquiring an additional 288,471 shares in the last quarter. Dimensional Fund Advisors LP grew its holdings in shares of IDEXX Laboratories by 4.3% in the first quarter. Dimensional Fund Advisors LP now owns 573,332 shares of the company’s stock valued at $322,145,000 after purchasing an additional 23,582 shares in the last quarter. Finally, Alyeska Investment Group L.P. increased its position in IDEXX Laboratories by 97.3% in the second quarter. Alyeska Investment Group L.P. now owns 401,082 shares of the company’s stock worth $211,146,000 after purchasing an additional 197,808 shares during the last quarter. 87.84% of the stock is currently owned by hedge funds and other institutional investors.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) develops and provides diagnostic, information technology, and related products and services for the animal health and water testing markets. The company primarily serves veterinary practices, helping them diagnose and monitor diseases through laboratory tests, in-clinic analyzers, software, and digital practice-management solutions.

IDEXX’s companion animal offerings include hematology, chemistry, urinalysis, immunodiagnostics, and imaging-related products, along with reference laboratory services and veterinary software.